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producing 
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To the Editor: Typhoid fever, 
caused by Salmonella enterica sero-
var Typhi, is a serious form of enteric 
fever. In 2000, the worldwide number 
of typhoid cases was estimated to be 
>21,000,000, and there were >200,000 
deaths from this disease (1).
Ciproﬂ  oxacin is the ﬁ  rst-line drug 
of choice for treatment of patients with 
typhoid fever, but there has been an in-
crease in strains resistant to ciproﬂ  ox-
acin (2) and resistance to third-gen-
eration cephalosporins has emerged 
(3). There are sporadic reports of high 
resistance to ceftriaxone in typhoidal 
salmonellae (3,4) in which CTX-M-
15 and SHV-12 extended spectrum 
β-lactamases (ESBLs) have been re-
ported. To date, there are no reports 
of  AmpC  β-lactamases in typhoidal 
salmonellae. AmpC β-lactamases con-
fer resistance to a broad spectrum of 
β-lactams, which greatly limits thera-
peutic options. We investigated an iso-
late of S. Typhi by using serotyping, 
antimicrobial drug susceptibility test-
ing, PCR screening for β–lactamase 
genes, and sequence analysis to con-
ﬁ  rm the identity of the isolate and the 
β–lactamase gene involved in confer-
ring resistance to this isolate. 
The isolate was obtained in Ban-
galore, India, in August 2009, from the 
blood of a female patient (14 years of 
age) who was hospitalized because of 
signs and symptoms of enteric fever. 
She had no history of having received 
antimicrobial drugs. After a blood 
sample was cultured, the patient was 
empirically treated with ceftriaxone 
but did not clinically improve.
Culture yielded gram-negative 
bacteria after 48 hours. The isolate 
was identiﬁ  ed by standard biochemi-
cal methods as S. Typhi. Identiﬁ  cation 
was conﬁ   rmed by using Salmonella 
spp. polyvalent O, O9, and H:d anti-
sera (Murex Biotech, Dartford, UK). 
Susceptibility to antimicrobial drugs 
was assessed by using the Kirby-Bau-
er disk diffusion method according 
to Clinical and Laboratory Standards 
Institute guidelines (www.clsi.org). 
The isolate was resistant to ampicil-
lin, piperacillin, cefoxitin, cefotaxime, 
ceftazidime, ceftriaxone, aztreonam, 
amoxicillin/clavulanate, and cefepime. 
It was susceptible to chloramphenicol, 
trimethoprim/sulfamethoxazole, na-
lidixic acid, ciproﬂ  oxacin, and mero-
penem.
Treatment was changed to cipro-
ﬂ  oxacin (500 mg every 12 h for 7 d). 
The patient recovered within 72 hours 
and was discharged. MICs were deter-
mined for ciproﬂ  oxacin, gatiﬂ  oxacin, 
oﬂ   oxacin, ceftazidime, ceftriaxone, 
and amoxicillin/clavulanate by using 
the Etest (AB Biodisk, Solna, Swe-
den) (Table). MIC for ceftriaxone was 
conﬁ  rmed by an agar dilution meth-
od (www.clsi.org). The isolate was 
tested for ESBLs by using a method 
with disks containing ceftazidime (30 
μg) and ceftazidime/clavulanate (30 
μg/10  μg). The AmpC disk test for 
detection of plasmid-mediated AmpC 
β-lactamase was conducted according 
to standard methods (5).
PCR screening and sequencing 
was performed to identify β-lactamase 
resistance genes blaTEM, blaSHV, blaOXA-1 
group, blaCTX-M, and AmpC as described 
(6,7). Sequencing of β-lactamase gene 
amplicons was conducted at the Vec-
tor Control Research Centre in Pondi-
cherry, India. The BLASTN program 
(www.ncbi.nlm.nih.gov/BLAST) was 
used for database searching. We also 
used a nested PCR speciﬁ   c for the 
ﬂ  agellin gene of S. Typhi to conﬁ  rm 
identity of the isolate (8). The nested 
PCR amplicon was sequenced to con-
ﬁ  rm identity of the ﬂ  agellin (ﬂ  iC) gene 
of S. Typhi. Sequencing of the ﬂ  agel-
lin gene product was conducted by 
Cistron Bioscience (Chennai, India).
The isolate was negative for 
ESBL production. PCR ampliﬁ  ca-
tion and sequencing showed that the 
isolate harbored blaTEM-1 and blaACC-1. 
The isolate was negative by PCR for 
other  β-lactamases tested. TEM-1 is 
one of the most commonly encoun-
tered β-lactamases in the family En-
terobacteriaceae and can hydrolyze 
narrow-spectrum penicillins and ce-
phalosporins.
We report ACC-1 AmpC 
β-lactamase in typhoidal salmonel-
lae. S. Typhi could have acquired the 
AmpC β- lactamase from drug-resis-
tant bowel ﬂ  ora. After the isolate was 
found to be highly resistant to ceftri-
axone, the change in therapy to cip-
roﬂ  oxacin helped in recovery of the 
patient without any sequelae.
ACC-1 AmpC β-lactamases origi-
nated in Hafnia alvei and are now 
found in various members of the fami-
ly Enterobacteriaceae (9). The ACC-1 
AmpC β-lactamases are exceptional in 
that they do not confer resistance to 
cephamycins (10). Our isolate con-
tained  blaTEM-1 and blaACC-1 and was 
resistant to cefoxitin and cefepime 
but susceptible to meropenem. Bidet 
et al. (9) reported isolating Klebsiella 
pneumoniae resistant to cefoxitin and 
cefepime and intermediate resistance 
to imipenem. Atypical resistance was 
attributed to ACC-1 β-lactamase pro-
duction and loss of a 36-kDa major 
outer membrane protein (9). We did 
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Table. MICs for isolate of Salmonella enterica serovar Typhi, Bangalore, India, 2009 
Drug MIC
Amoxicillin/clavulanic acid  >256
Piperacillin/tazobactam 12
Ceftazidime >256
Cefotaxime >256
Ceftriaxone >256
Ciprofloxacin 0.094 LETTERS
not analyze changes in the outer mem-
brane proteins responsible for altera-
tion of permeability.
Continual monitoring of drug 
resistance patterns is imperative. An-
timicrobial drug susceptibility test-
ing should be conducted for clinical 
isolates, and empirical antimicrobial 
drug therapy should be changed ac-
cordingly.  AmpC  β-lactamase genes 
will eventually be transferred to ty-
phoidal salmonellae, which may pose 
a threat to public health. Spread of 
broad-spectrum  β-lactamases would 
greatly limit therapeutic options and 
leave only carbapenems and tige-
cycline as secondary antimicrobial 
drugs.
Bindiganavile N. Gokul, 
Godfred A. Menezes, 
and Belgode N. Harish
Author afﬁ  liations: Sri Devaraj Urs Medical 
College, Kolar, India (B.N. Gokul, G.A. Me-
nezes); Fortis Hospitals, Bangalore, India 
(B.N. Gokul); and Jawaharlal Institute of 
Postgraduate Medical Education and Re-
search, Pondicherry, India (G.A. Menezes, 
B.N. Harish)
DOI: 10.3201/eid1607.091643
References
  1.   Crump JA, Luby SP, Mintz ED. The glob-
al burden of typhoid fever. Bull World 
Health Organ. 2004;82:346–53.
    2.   Harish BN, Menezes GA, Sarangapani 
K, Parija SC. A case report and review of 
the literature: ciproﬂ  oxacin resistant Sal-
monella enterica serovar Typhi in India. 
J Infect Dev Ctries. 2008;2:324–7. DOI: 
10.3855/jidc.229
  3.   Al Naiemi N, Zwart B, Rijnsburger MC, 
Roosendaal R, Debets-Ossenkopp YJ, 
Mulder JA, et al. Extended-spectrum-beta-
lactamase production in a Salmonella en-
terica serotype Typhi strain from the Phil-
ippines. J Clin Microbiol. 2008;46:2794–5. 
DOI: 10.1128/JCM.00676-08
  4.   Rotimi  VO,  Jamal  W,  Pal  T,  Sovenned 
A, Albert MJ. Emergence of CTX-M-15 
type extended-spectrum β-lactamase-
producing  Salmonella spp. in Kuwait 
and the United Arab Emirates. J Med Mi-
crobiol. 2008;57:881–6. DOI: 10.1099/
jmm.0.47509-0
  5.   Singhal S, Mathur T, Khan S, Upadhay 
DJ, Chugh S, Gaind R, et al. Evaluation 
of methods for AmpC beta-lactamase in 
gram negative clinical isolates from ter-
tiary care hospitals. Indian J Med Micro-
biol. 2005;23:120–4. DOI: 10.4103/0255-
0857.16053
    6.    Mabilat C, Goussard S. PCR detection 
and identiﬁ  cation of genes for extended 
spectrum β-lactamases. In: Persiang DH, 
Smith TF, Tenover FC, White TJ, edi-
tors. Diagnostic molecular microbiology: 
principles and applications. Washington: 
American Society for Microbiology; 
1993. p. 553–9.
    7.   Pérez-Pérez FJ, Hanson ND. Detection 
of plasmid-mediated AmpC  β-lactamase 
genes in clinical isolates by using multiplex 
PCR. J Clin Microbiol. 2002;40:2153–62. 
DOI: 10.1128/JCM.40.6.2153-2162.2002
  8.   Frankel G, Newton SM, Schoolnik GK, 
Stocker BA. Unique sequences in region 
VI of the ﬂ   agellin gene of Salmonella 
typhi. Mol Microbiol. 1989;3:1379–
83. DOI: 10.1111/j.1365-2958.1989.
tb00119.x
  9.   Bidet P, Burghoffer B, Gautier V, Brahimi 
N, Mariani-Kurkdjian P, El-Ghoneimi A, 
et al. In vivo transfer of plasmid-encoded 
ACC-1  ampC from Klebsiella pneumo-
niae to Escherichia coli in an infant and 
selection of impermeability to imipenem 
in  K. pneumoniae. Antimicrob Agents 
Chemother. 2005;49:3562–5. DOI: 
10.1128/AAC.49.8.3562-3565.2005
10.   Bauernfeind A, Schneider I, Jungwirth 
R, Sahly H, Ullmann U. A novel type of 
AmpC  β-lactamase, ACC-1, produced 
by a Klebsiella pneumoniae strain caus-
ing nosocomial pneumonia. Antimicrob 
Agents Chemother. 1999;43:1924–31.
Address for correspondence: Belgode N. Harish, 
Department of Microbiology, Jawaharlal 
Institute of Postgraduate Medical Education and 
Research, Pondicherry 605006, India; email: 
drbnharish@yahoo.com
Endocarditis 
Caused by 
Actinobaculum 
schaalii, Austria
To the Editor: In May 2009, a 
52-year-old man was hospitalized 
with middle cerebral artery stroke and 
fever of unknown origin. He had a 
complicated medical history of middle 
cerebral artery stroke and mechanical 
valve replacement of the aortic valve 
2 years earlier and gastric-duodenal 
angiodysplasia. Two months before 
the most recent hospitalization, he had 
been hospitalized because of fever and 
anemia; blood cultures were positive; 
Gram stain identiﬁ  ed coryneform rods 
that did not grow in culture. Antimi-
crobial drug therapy with levoﬂ  oxacin 
(400 mg 1×/d) was initiated, and the 
patient was discharged.
At the most recent admission, 
laboratory testing showed a leukocyte 
count of 5.92 × 103 cells/μL, with 81% 
neutrophils, 7% lymphocytes, and 9% 
monocytes; thrombocyte count was 
338 × 103 cells/μL. C-reactive protein 
level was 62.6 mg/L (reference value 
<8 mg/L). Basic serum and urine 
chemical proﬁ   les and urine culture 
were unremarkable. Empiric antimi-
crobial drug therapy with piperacillin–
tazobactam (4.5 g 3×/d) was initiated 
and discontinued after 5 days because 
of clinical improvement. The next 
day, the patient’s condition deteriorat-
ed, C-reactive protein level increased 
from 15 mg/L to 32 mg/L, and blood 
was collected for culture on the day 
after piperacillin-tazobactam discon-
tinuation and the next 2 days. After 4 
days of incubation, bacterial growth 
was detected in 1 aerobic and 3 an-
aerobic samples. Gram stain showed 
positive coryneform rods. Within 48–
72 hours, the isolate yielded growth 
on blood, chocolate, and Schaedler 
agar; colonies were 1–2 mm in di-
ameter and gray. The speciﬁ  city  of 
the organism was unsatisfactory with 
the system we used (API Coryne sys-
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